{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=New+FVIII+products",
    "query": {
      "intervention": "New FVIII products"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T22:17:27.601Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05036278",
      "title": "Prophylaxis Regimen for Hemophilia A Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A",
        "Prophylaxis of Bleeding"
      ],
      "interventions": [
        {
          "name": "Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2022-07-28",
      "completion_date": "2024-09-12",
      "has_results": true,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-09-17T22:17:27.601Z",
      "location_count": 12,
      "location_summary": "Loma Linda, California • Los Angeles, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05036278"
    },
    {
      "nct_id": "NCT03603275",
      "title": "Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "New FVIII products",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2018-08-06",
      "completion_date": "2020-05-14",
      "has_results": false,
      "last_update_posted_date": "2022-08-25",
      "last_synced_at": "2026-09-17T22:17:27.601Z",
      "location_count": 27,
      "location_summary": "La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 23 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03603275"
    },
    {
      "nct_id": "NCT02546622",
      "title": "ATHN 2: Factor Switching Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "American Thrombosis and Hemostasis Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 310,
      "start_date": "2015-09",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-12-09",
      "last_synced_at": "2026-09-17T22:17:27.601Z",
      "location_count": 27,
      "location_summary": "San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02546622"
    },
    {
      "nct_id": "NCT02674997",
      "title": "GAS-Hem Feasibility Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Factor VIII",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "5 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2016-08-05",
      "completion_date": "2016-11-02",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-09-17T22:17:27.601Z",
      "location_count": 2,
      "location_summary": "Peoria, Illinois • Portland, Oregon",
      "locations": [
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02674997"
    },
    {
      "nct_id": "NCT04690322",
      "title": "POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A",
        "Factor VIII"
      ],
      "interventions": [
        {
          "name": "Eloctate",
          "type": "DRUG"
        },
        {
          "name": "Adynovate",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-04-15",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-09-17T22:17:27.601Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04690322"
    }
  ]
}